Clinical trials: Localized Prostate Cancer, active
Localized Prostate Carcinoma
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
Patients with prostate cancer who are candidates for stereotactic radiotherapy to the prostate and seminal vesicles will undergo staging exams, which will include prostate specific membrane antigen (PSMA) positron emission…
- Trial name
- PRO-FAST (NCT05936736)
- Testing
- prostate SBRT
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Intermediate Risk Prostate Cancer (Diagnosis), Prostate Cancer
Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT07674225)
- Testing
- Prostate radical radiotherapy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
New Treatment Modalities for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of four of the nowadays most established primary treatments for patients with clinically localized prostate cancer (active surveillance, robot-assisted radical…
- Trial name
- TTOPROST/OBS (NCT05523856)
- Testing
- Active Surveillance, Robot-Assisted Radical Prostatectomy, Intensity-Modulated Radiotherapy
- Volunteers
- 480 people
- Sponsor
- Fundacion IMIM
Prostate Cancer
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer
As the most common carcinoma in men, prostate cancer is a significant tumor entity in oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent therapy alternative in the non-metastatic primary…
- Trial name
- SMILE (NCT04845503)
- Testing
- MR-guided Radiotherapy
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer.
- Trial name
- PrTK03 (NCT01436968)
- Testing
- Aglatimagene besadenovec + valacyclovir
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 711 people
- Sponsor
- Candel Therapeutics, Inc.
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two…
- Trial name
- NCT07325721
- Testing
- Hypofractionated radiation with a microboost
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Medical University of South Carolina
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Prostate Cancer
Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer
The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days.
- Trial name
- HERMES (NCT04595019)
- Testing
- SBRT
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Adenocarcinoma
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is…
- Trial name
- BiolenRT (NCT04943536)
- Testing
- bicalutamide, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alessa Therapeutics Inc.
Prostate Cancer, Prostate Neoplasm
Effectiveness of Focal Therapy in Men With Prostate Cancer
In the Netherlands, most men with prostate cancer (PCa) are treated with radical whole-gland treatment, i.e. prostatectomy or radiotherapy.
- Trial name
- ENFORCE (NCT06223295)
- Testing
- Focal therapy, Usual care
- Where
- 5 sites in Netherlands
- Volunteers
- 356 people
- Sponsor
- Radboud University Medical Center
Prostate Carcinoma
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy.
- Trial name
- NCT02960087
- Testing
- Low dose rate brachytherapy, High dose rate brachytherapy
- Where
- 7 sites in Canada
- Volunteers
- 334 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and…
- Conditions
- Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT03902951
- Testing
- Abiraterone Acetate, Apalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.
- Trial name
- INCLUDE PC (NCT07407686)
- Testing
- Surveys, Semi-structured interviews and focus groups
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making
In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer.
- Trial name
- NCT05923684
- Testing
- NLP-based Feedback
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Prostate Cancer
¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer
Multiparametric magnetic resonance imaging (mpMRI) is the standard imaging modality for prostate cancer diagnosis and focal therapy planning.
- Trial name
- FOCUS-PSMA (NCT07788625)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Prostate Cancer, Localized Prostate Carcinoma
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits…
- Trial name
- NCT02526368
- Testing
- Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Ivan de Kouchkovsky, MD
Prostate Cancer
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
- Trial name
- VAPOR 2 (NCT05683691)
- Testing
- Vanquish System
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Francis Medical Inc.
Erectile Dysfunction Due to Arterial Insufficiency, Erectile Dysfunction
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
The purpose of this study to perform a randomized, sham controlled analysis of the effectiveness of both fSWT and rWT in the relief of erectile dysfunction and chronic pelvic pain syndrome.
- Conditions
- Erectile Dysfunction Due to Arterial Insufficiency, Erectile Dysfunction, Erectile Dysfunction Due to Arterial Disease, Chronic Pelvic Pain Syndrome
- Trial name
- Shockwave (NCT05868668)
- Testing
- Focused shockwave, Radial wave
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer
SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial
This study will test a web-based supportive care program called the Support, Communication, and Information Program for Prostate Cancer - Interactive (SCIPI).
- Trial name
- SCIPI (NCT07280897)
- Testing
- SCIPI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The University of Texas Health Science Center at San Antonio